jaebm.blogg.se

Brave health series b
Brave health series b








brave health series b brave health series b

Understanding the life course health trajectories of people who survive COVID-19 and how their process of aging becomes affected by that acute experience is vital. From a population aging perspective, it seems equally important to focus on those lives that are not lost outright, but still strongly affected by the harsh legacy of Severe Acute Respiratory Syndrome coronavirus type 2 (SARS-CoV-2). In the process, it summarizes lessons from established patient populations aging with progressive lung disease-using cystic fibrosis as a prominent example from the author’s lived experience-that may enhance the experiences of older COVID-19 survivors.Īging, COVID-19, Health care, Illness management, Pulmonary fibrosisĪs the COVID-19 pandemic continues to ravage communities worldwide, much attention is appropriately given to the many lives being lost to the disease. It also outlines the relevance of findings from this research for clinical care supporting people newly aging with advanced lung disease from COVID-19. This article outlines key priorities for research with COVID-19 survivors aging with permanent lung damage and highlights unique considerations for people older at age of onset. Supporting healthy aging for these patients will require both gathering data about their unique experiences and using the existing evidence basis about adapting to managing obstructive lung disease. Survivors of all ages who have extensive lung impacts are likely to be new to managing those issues. Among older patients, advanced lung damage is more likely. As the COVID-19 pandemic continues to affect communities worldwide, this novel disease is leaving many survivors with severe lung damage.










Brave health series b